Return to Headlines
150 views
Email RSS

Relatively Good Cash Flow Detected in Shares of Combinatorx in the Biotechnology Industry (CRXX, TRGT, NABI, ENZN, INCY)

Written on Fri, 07/30/2010 - 4:10am
By Chip Brian

Below are the top five companies in the Biotechnology industry as measured by the price to cash flow ratio. Often companies with the lowest ratio present the greatest value to investors.
Combinatorx (NASDAQ:CRXX) has a price to free cash flow ratio of 3.3x based on a current price of $1.54 and a free cash flow per share of $0.47.
Targacept (NASDAQ:TRGT) has a price to free cash flow ratio of 3.4x based on a current price of $21 and a free cash flow per share of $6.12.
Nabi Biopharmaceuticals (NASDAQ:NABI) has a price to free cash flow ratio of 5.6x based on a current price of $5.56 and a free cash flow per share of $1.
Enzon Pharmaceuticals (NASDAQ:ENZN) has a price to free cash flow ratio of 14.9x based on a current price of $10.87 and a free cash flow per share of $0.73.
Incyte (NASDAQ:INCY) has a price to free cash flow ratio of 15.1x based on a current price of $12.95 and a free cash flow per share of $0.86.
SmarTrend is bullish on shares of CRXX and our subscribers were alerted to Buy on January 27, 2010 at $1.21. The stock has risen 27.8% since the alert was issued.


Company Information For: CRXX

Contact Chip Brian
Smartrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.mysmartrend.com.

Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at http://www.mysmartrend.com/morning-call-newsletter-signup.